RFP - Supply of contraceptive implants

Medicines RFP Closed

PHARMAC invites proposals for the supply of contraceptive implants in New Zealand.

This request for proposals (RFP) letter incorporates the following schedules:

  • Schedule 1 specifies the pharmaceuticalfor which PHARMAC is requesting proposals and sets out the background to the RFP and the types of proposals sought;
  • Schedule 2 describes the process that PHARMAC expects to follow in relation to the RFP;
  • Schedule 3 sets out information about the estimated size of the current subsidised market for the pharmaceutical; and
  • Schedule 4 contains the RFP form in which you are to provide details of your proposal.

If you wish to submit a proposal, you must submit it to PHARMAC no later than 5.00 p.m. on Friday 11 April, 2014

If you have any questions about this RFP, please contact Bronwyn Hale at PHARMAC by email (bronwyn.hale@pharmac.govt.nz).

We look forward to receiving your proposal.

Schedule 1: Pharmaceutical, background to RFP and types of proposals sought

1.       Pharmaceutical

  1. PHARMAC is interested in considering any proposal from suppliers of hormonal long acting reversible contraceptives in the presentation of an implant (hereinafter referred to as “contraceptive implants”) as a progesterone only method of contraception.

2.        Background to RFP

The background to this RFP is as follows:

  1. On 1 August 2010 following an RFP for the supply of hormonal long-acting reversible contraceptives, PHARMAC listed the contraceptive implant brand ‘Jadelle’, awarding Sole Subsidised Supply status in Section B of the Pharmaceutical Schedule and listing in Part II of Section H of the Pharmaceutical Schedule. The Sole Subsidised Supply period for Jadelle ended on the 31 December 2013.
  2. PHARMAC is again interested in considering proposals that would result in a sole supply listing of a contraceptive implant in Section B and Part II of Section H of the Pharmaceutical Schedule.

3.        Types of proposals sought

Schedule 2: RFP process

PHARMAC expects to follow the process set out below in the sequence indicated.

1.        Submission

  1. You may submit more than one proposal.  Each proposal will be considered as a separate proposal.
  2. Proposals must be submitted no later than 5.00 p.m. (New Zealand time) on Friday 11 April 2014. Late proposals will only be considered at PHARMAC’s discretion.
  3. You cannot withdraw your proposal, once submitted, while the RFP process is continuing.
  4. All proposals must be submitted to PHARMAC to the attention of Bronwyn Hale, Therapeutic Group Manager either by facsimile (+64 4 460 4995) or email (Bronwyn.hale@pharmac.govt.nz).  Email is preferred.

2.        Evaluation

3.        PHARMAC may request further information

  1. PHARMAC may request such further information as it considers necessary from or about you for the purposes of clarifying or evaluating your proposal, including (but not limited to) a sample of the product included in your proposal (and if you intend supplying this in a different form from that sample, information about the form in which it would be supplied) in which case you must supply that information within 10 business days of PHARMAC requesting it.
  2. If PHARMAC requests further information from or about you it is not obliged to request the same or any other information form or about any other party.

4.       Negotiation 

  1. PHARMAC may negotiate with the submitter(s) of one or more preferred proposals, in the latter case whether or not the acceptance of either supplier’s proposal would exclude acceptance of the other proposal.
  2. Negotiations will proceed on the basis that PHARMAC’s standard terms and conditions for supply of pharmaceuticals, which are available on request from PHARMAC, will apply.
  3. Given that PHARMAC expects your proposal to be the best you can offer, PHARMAC does not intend to initiate negotiation with you on price.  However, PHARMAC does not exclude the possibility that the final price agreed will be different from the price put forward in your proposal, as a result of the impact that other negotiated terms may have on price.
  4. PHARMAC may negotiate and enter into a provisional agreement with a preferred supplier(s) on whatever special terms, in addition to PHARMAC’s standard terms and conditions, PHARMAC considers appropriate.
  5. If PHARMAC and the supplier(s) are unable to reach a provisional agreement within what PHARMAC considers to be a reasonable time, PHARMAC may terminate those negotiations and negotiate with a different supplier(s).

 5.       Consultation and approval 

6.         Miscellaneous 

PHARMAC may consult with you before deciding whether to disclose Confidential Information for the purposes described in sub-clauses (i) to (iv) above. You acknowledge, however, that it is for PHARMAC to decide, in its absolute discretion, whether it is necessary or appropriate to disclose information for any of the above purposes, provided that PHARMAC shall act in good faith in disclosing any Confidential Information.

7.         Anticipated timetable

Schedule 3: Current listing and market information

The following information relates to the estimated subsidised market size of contraceptive implants in the community.

The information is approximate and indicative only. PHARMAC makes no representation as to the accuracy of this information or as to the level of sales or likely sales of contraceptive implants and, while PHARMAC has taken all reasonable care in preparing the information set out below, it accepts no liability for any errors or omissions in the information. PHARMAC is not obliged to notify you in the event of any change to the figures below.

PHARMAC wish to advise that market dynamics and therefore the data below may be subject to change with the absence or inclusion of other long term contraceptives that may be sole supply on the pharmaceutical schedule.

The estimated number of dispensings of contraceptive implants in the community for the financial years ending 30 June 2011, 30 June 2012 and 30 June 2013.

Pharmaceutical and presentation July 2010 to June 2011 July 2011 to June 2012 July 2012 to June 2013
Levonorgestrel implants 10,264 13,965 12,914

Schedule 4: Proposal form

Read the proposal form in the full PDF of this RFP [PDF, 133 KB] or contact Bronwyn Hale for an editable Word version (bronwyn.hale@pharmac.govt.nz).